公开(公告)号：US20170002331A1

公开(公告)日：2017-01-05

申请号：US15101586

申请日：2014-12-02

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Boon Hwa Andre Choo ,  Jiyun Zheng

IPC: C12N5/16 ,  C12N5/00 ,  C07K16/18

CPC classification number: C12N5/163 ,  C07K16/18 ,  C07K16/44 ,  C07K2317/35 ,  C07K2317/565 ,  C07K2317/73 ,  C12N5/0081

Abstract: An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fucα1-2Galβ1-3GlcNAc1-3Galβ1 or Fucα1-2Galβ1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.

Abstract translation: 公开了结合糖基化蛋白质的抗体，其中糖基化包括聚糖基序Fucα1-2Galβ1-3GlcNAc1-3Galβ1或Fucα1-2Galβ1-3GlcNAc。 还公开了对未分化多能细胞具有细胞毒性的抗体。

公开(公告)号：US11306153B2

公开(公告)日：2022-04-19

申请号：US16303657

申请日：2017-05-22

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Mei Yee Vanessa Ding ,  Boon Hwa Andre Choo ,  Wey Jia Fong

IPC: C07K16/40 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00 ,  C07K19/00

Abstract: The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment conjugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, therapeutic use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.

公开(公告)号：US11512292B2

公开(公告)日：2022-11-29

申请号：US16545736

申请日：2019-08-20

Applicant: Agency for Science, Technology and Research

Inventor： Boon Hwa Andre Choo ,  Jiyun Zheng

IPC: C07K16/18 ,  C12N5/16 ,  C07K16/44 ,  C12N5/00

Abstract: An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1 or Fucα1-2Galβ1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.

公开(公告)号：US10428312B2

公开(公告)日：2019-10-01

申请号：US15101586

申请日：2014-12-02

Applicant: Agency for Science, Technology and Research

Inventor： Boon Hwa Andre Choo ,  Jiyun Zheng

IPC: C07K16/00 ,  C12N5/16 ,  C07K16/18 ,  C07K16/44 ,  C12N5/00

Abstract: An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fucα1-2Galβ1-3GlcNAc1-3Galβ1 or Fucα1-2Galβ1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.

公开(公告)号：US10287547B2

公开(公告)日：2019-05-14

申请号：US15303520

申请日：2014-04-11

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  SINGAPORE HEALTH SERVICES PTE LTD

Inventor： Mei Yee Vanessa Ding ,  Boon Hwa Andre Choo ,  Chui Ping Angela Chin ,  Jodhbir Singh Mehta ,  Gary Peh

IPC: C12N5/12 ,  C12N5/079 ,  C07K16/28 ,  C07K16/18 ,  C07K16/40

Abstract: This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hCENCs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed Peroxiredoxin-6 (Prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal endothelial cells from a mixture of cell.